Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GENEVA: Neovasculgen + Endovascular Treatment for Severe Limb Ischemia
NCT06473740Phase 4Recruiting
- Sponsor
- Amur State Medical Academy
- Start
- Jun 2024
- Primary completion
- May 2027
- Modality
- Gene Editing, Gene Silencing, Plasmid DNA
- Countries
- 1
01
Overview
A Phase 4 trial of neovasculgen in lower limb ischemia, sponsored by Amur State Medical Academy. Started Jun 2024; status: recruiting.
02
Drugs
neovasculgen
03
Conditions
lower limb ischemia
Beyond the preview
Go deeper on NCT06473740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06473740.